Invivoscribe FLT3 ITD MRD Assay for RUO

This news item was updated in July 2024

Stratifying acute myeloid leukemia (AML) disease according to molecular genetic alterations, such as those in the fms related tyrosine kinase 3 (FLT3) gene, aids in prognosis1. The most frequent and clinically significant type of FLT3 mutation is an internal tandem duplication (ITD) in the juxtamembrane domain2. The FLT3-ITD mutation occurs in about 25% of newly diagnosed AML patients and is associated with an increased risk of relapse and lower overall survival rate1. Unlike flow cytometry assays which require fresh sample and are highly subjective, the FLT3 ITD MRD Assay, a targeted, deep sequencing assay can be used with previously isolated DNA to detect ITD mutations at an allelic sensitivity level of 5×10-5.

Invivoscribe’s FLT3 ITD MRD Assay includes 24 unique dual-indices enabling the ability to multiplex multiple samples. This kit configuration provides laboratories the flexibility to scale testing for variable AML MRD research needs. To further simplify your workflow, our FLT3 ITD MRD Software can easily be integrated into down-stream reporting systems and/or LIMS to automate data analysis.

Key benefits

• In-house MRD testing for faster, cost-effective results
• Streamlined workflow reduces errors and TAT
• Flexibility to multiplex samples
• Use previously isolated DNA enabling sample batching
• Dockerized software enables highly portable, flexible and efficient sample analysis
• Standardized for international collaboration

Ordering information

REFERENCES

1. Naval Daver, et al. (2019) Leukemia. 33:299-312.
2. Heiko Konig, Mark Levis, (2015) Expert Opin. Ther. Targets. 19(1): 37-54

Bio-Connect supplies Invivoscribe products in the Benelux. If you have any questions, please contact the helpdesk.